Navigation Links
Peregrine Researchers Report Data Showing Bavituximab's Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Date:9/7/2007

btaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Barbara Lindheim

(800) 987-8256 (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
4. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
5. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
6. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
7. NIEHS Researchers Identify Enzyme Critical in DNA Replication
8. Stanford Researchers Find Brain Pathway of Depression in Rats
9. Researchers Discover Method for Identifying How Cancer Evades the Immune System
10. Researchers Discover Gene For Rare Skin Disorder
11. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs 4616 1Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs 4616 2Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs 4616 3Scientists identify gene vital to early embryonic cells forming a normal heart and skull 12703 1Scientists identify gene vital to early embryonic cells forming a normal heart and skull 12703 2Nurses Decry Cruel Ruse of GOP Health Plan 49441 1